We have located links that may give you full text access.
Routine screening of anal cytology in HIV-infected subjects and the impact on invasive anal cancer. A prospective cohort study.
Clinical Infectious Diseases 2019 September 5
BACKGROUND: The efficacy of screening programs to prevent anal cancer in HIV-1-infected subjects is unclear.
AIM: To examine the impact of a screening program to detect anal cancer precursors on the incidence of cases of invasive-anal-squamous-cell-carcinoma (IASCC) in HIV-1-infected subjects.
PATIENTS AND METHODS: Single-center, retrospective analysis of a prospective cohort of HIV-1-infected outpatients attending a reference HIV Unit from January 2005 onward. All participants were invited to participate in a continued structured screening program for anal cancer prevention. We estimated the incidence of IASCC and performed a comparative analysis between subjects enrolled in the screening program (screening group) and those who declined to participate (non-screening group). To reduce any selection bias, a propensity score analysis was applied.
RESULTS: 3111 HIV-1-infected subjects [1596 men-who-have-sex-with-men (MSM), 888 men-who-have-sex-with-women (MSW), 627 women] were included (mean age 41 years), median follow-up 4.7 years (14,595 patient/years of follow-up). Of them, 1691 (54%) participated in the screening program. Ten patients were diagnosed with IASCC: two of them (MSM) in the screening group and eight (4 MSM, 2 MSW and 2 women) in the non-screening one. The incidence rate of IASCC was 21.9 (95%CI:2.7-70.3) and 107.0 (95%CI:46.2-202.0) per 100,000 person-years, respectively. After a propensity score adjustment, the difference was significant in favour to the screening group (HR:0.17, 95%CI:0.03-0.86).
CONCLUSIONS: The number of cases of IASCC was significantly lower in HIV-infected subjects engaged in an anal cytology screening program. These results should be validated in a randomized clinical trial.
AIM: To examine the impact of a screening program to detect anal cancer precursors on the incidence of cases of invasive-anal-squamous-cell-carcinoma (IASCC) in HIV-1-infected subjects.
PATIENTS AND METHODS: Single-center, retrospective analysis of a prospective cohort of HIV-1-infected outpatients attending a reference HIV Unit from January 2005 onward. All participants were invited to participate in a continued structured screening program for anal cancer prevention. We estimated the incidence of IASCC and performed a comparative analysis between subjects enrolled in the screening program (screening group) and those who declined to participate (non-screening group). To reduce any selection bias, a propensity score analysis was applied.
RESULTS: 3111 HIV-1-infected subjects [1596 men-who-have-sex-with-men (MSM), 888 men-who-have-sex-with-women (MSW), 627 women] were included (mean age 41 years), median follow-up 4.7 years (14,595 patient/years of follow-up). Of them, 1691 (54%) participated in the screening program. Ten patients were diagnosed with IASCC: two of them (MSM) in the screening group and eight (4 MSM, 2 MSW and 2 women) in the non-screening one. The incidence rate of IASCC was 21.9 (95%CI:2.7-70.3) and 107.0 (95%CI:46.2-202.0) per 100,000 person-years, respectively. After a propensity score adjustment, the difference was significant in favour to the screening group (HR:0.17, 95%CI:0.03-0.86).
CONCLUSIONS: The number of cases of IASCC was significantly lower in HIV-infected subjects engaged in an anal cytology screening program. These results should be validated in a randomized clinical trial.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app